Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction.
10.1007/s11655-022-3676-7
- Author:
Yue CHEN
1
;
Yu-Ying XU
2
;
Hai-Jun JIANG
3
;
Lei WANG
2
;
Jia-Wei ZHAI
1
;
Tong ZHANG
2
;
Yu-Fei YANG
4
Author Information
1. Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
2. Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
3. Department of Oncology, Central Hospital of Ankang City, Ankang, Shaanxi Province, 725000, China.
4. Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. yyf93@vip.sina.com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Jianpi Bushen Jiedu Decoction;
S-1;
apatinib;
clinical trial;
metastatic colorectal cancer;
progression-free survival
- MeSH:
Adult;
Aged;
Antineoplastic Agents/therapeutic use*;
Colonic Neoplasms;
Female;
Humans;
Male;
Middle Aged;
Pyridines;
Thrombocytopenia/drug therapy*;
Transaminases/therapeutic use*
- From:
Chinese journal of integrative medicine
2022;28(10):924-929
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To evaluate the effect and safety of low-dose of apatinib and S-1 combined with Jianpi Bushen Jiedu Decoction (JBJD) in patients with metastatic colorectal cancer (mCRC) who have failed second or above lines treatment, in order to provide more treatment option for mCRC patients by integrated medicine.
METHODS:Thirteen patients were selected from a single-arm, open-label clinical study from April 2019 to September 2020. The patients were treated with low-dose apatinib (250 mg, once a day) and S-1 (20 mg, twice a day) combined with JBJD for at least one cycle and were followed up to August 2021. The primary endpoint was disease progression-free survival (PFS). Disease control rate (DCR), objective response rate (ORR), and overall survival (OS) of patients were observed as the secondary endpoints. Adverse events were recorded as well.
RESULTS:The average age of the 13 patients was 56.5 ±13.0 years and 76.9% were male. The median PFS and median OS were 4.6 and 8.3 months, respectively. The ORR was 7.7% (1/13) while the DCR was 61.5% (8/13). The common adverse events were hypertension, proteinuria, elevated transaminase, and thrombocytopenia. One patient experienced thrombocytopenia of grade 3.
CONCLUSIONS:Patients with mCRC after failure of the second or above lines of treatment may potentially benefit from the treatment of low-dose apatinib and S-1 combined with JBJD because of its similar effect as the standard dose of target therapy and relatively better safety. (Registration No. ChiCTR1900022673).
